Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy.
Brief Summary: Objectives:

Primary objective:

To evaluate the effects on retinal morphophysiology of full scatter single target panretinal photocoagulation (PRP) versus full scatter multiple target panretinal photocoagulation (both combined with intravitreous injections of ranibizumab) versus intravitreous ranibizumab (IVR) alone in patients with proliferative diabetic retinopathy (PDR).

Primary outcome:

The primary endpoint for this study is the mean change in the total area of active retinal neovessels, as measured by fluorescein angiography leakage area, in mm2, from baseline to week 48.

Secondary objectives:

* To assess the mean changes in best corrected visual acuity (BCVA), the mean changes in central subfield foveal thickness (CSFT), the mean changes in wave B amplitude and oscillatory potentials on a full-field electroretinogram (ERG), and the mean changes on the peripheral visual field by static perimetry (30:2 strategy), from baseline to week 48.
* To assess the incidence of adverse events during the study.

Strategic goal:

In the era of anti-VEGF treatment for retinal neovascularization 1, 2, 3, 4 , it is time to determine what would be the best association of PRP + anti-VEGF for proliferative diabetic retinopathy (PDR), or still, if just intravitreal anti-VEGF treatment would be even better regarding morphologic (new vessels area and CSFT) and functional parameters (BCVA, ERG response and visual field).


Options:
A: Arm Label: SS-PRP arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravitreal Ranibizumabe, Drug: panfotocoagulation (PRP) single shoot (ETDRS) | Arm Label: MS-PRP arm; Type: EXPERIMENTAL; Interventions: Drug: Intravitreal Ranibizumabe, Drug: panfotocoagulation (PASCAL) | Arm Label: IVR arm; Type: OTHER; Interventions: Drug: Intravitreal Ranibizumabe | Intervention Type: DRUG; Name: Intravitreal Ranibizumabe; Assigned to Arm(s): IVR arm, MS-PRP arm, SS-PRP arm | Intervention Type: DRUG; Name: panfotocoagulation (PASCAL); Assigned to Arm(s): MS-PRP arm | Intervention Type: DRUG; Name: panfotocoagulation (PRP) single shoot (ETDRS); Assigned to Arm(s): SS-PRP arm
B: Arm Label: 7 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: 20 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: sham; Type: SHAM_COMPARATOR; Interventions: Other: sham | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 20 days, 7 days | Intervention Type: OTHER; Name: sham; Assigned to Arm(s): sham
C: Arm Label: A: Faricimab 6 mg Q8W; Type: EXPERIMENTAL; Interventions: Drug: Faricimab, Procedure: Sham Procedure | Arm Label: B: Faricimab 6 mg PTI; Type: EXPERIMENTAL; Interventions: Drug: Faricimab, Procedure: Sham Procedure | Arm Label: C: Aflibercept 2 mg Q8W; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aflibercept, Procedure: Sham Procedure | Intervention Type: DRUG; Name: Aflibercept; Assigned to Arm(s): C: Aflibercept 2 mg Q8W | Intervention Type: DRUG; Name: Faricimab; Assigned to Arm(s): A: Faricimab 6 mg Q8W, B: Faricimab 6 mg PTI | Intervention Type: PROCEDURE; Name: Sham Procedure; Assigned to Arm(s): A: Faricimab 6 mg Q8W, B: Faricimab 6 mg PTI, C: Aflibercept 2 mg Q8W
D: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Sham injection/ranibizumab 0.5 mg; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab 0.3 mg, Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection/ranibizumab 0.5 mg

Answer: A